Figure 2. Response per Lugano criteria... | American Society of Hematology

Figure 2.

$Response per Lugano criteria by investigator assessment in prespecified groups. (A) ORRs and (B) CR rates. aBulky disease per investigator. bRefractory: disease progression or stable disease as best response to therapy or disease progression within 6 months after completion of therapy. cPrimary refractory: refractory to 1L antilymphoma therapy. dDouble refractory: refractory to both anti-CD20 and an alkylating agent. 3L+, received epcoritamab plus R2 in the third line or later; FLIPI, Follicular Lymphoma International Prognostic Index; POD24 2L, progression of disease within 24 months after 1L therapy and received epcoritamab plus R2 in the 2L.$

Response per Lugano criteria by investigator assessment in prespecified groups. (A) ORRs and (B) CR rates. ^aBulky disease per investigator. ^bRefractory: disease progression or stable disease as best response to therapy or disease progression within 6 months after completion of therapy. ^cPrimary refractory: refractory to 1L antilymphoma therapy. ^dDouble refractory: refractory to both anti-CD20 and an alkylating agent. 3L+, received epcoritamab plus R² in the third line or later; FLIPI, Follicular Lymphoma International Prognostic Index; POD24 2L, progression of disease within 24 months after 1L therapy and received epcoritamab plus R² in the 2L.

This Feature Is Available To Subscribers Only